Biogen Inc.

Key Statistics

Recent News

• What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names Insider Monkey

  Denali Therapeutics Inc. (NASDAQ:DNLI) is one of the 10 best AI driven biotech stocks to invest in. On May 22, Denali Therapeutics Inc. (NASDAQ:DNLI) halted its joint work with Biogen Inc. (NASDAQ:BII

• 1 Cash-Producing Stock with Impressive Fundamentals and 2 We Find Risky StockStory

  While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competit

• How Is Biogen’s Stock Performance Compared to Other Biotech Stocks? Barchart

  Biogen has recently outperformed its industry peers, and analysts remain reasonably upbeat about the stock’s prospects.

• Should Biogen’s (BIIB) New SMA Breakthrough and Lupus Data Prompt a Fresh Look From Investors? Simply Wall St.

  In early June 2026, Biogen reported that the FDA granted Breakthrough Therapy Designation to its investigational SMA treatment salanersen, while also, alongside UCB, presenting additional positive Pha

• A Look At Biogen (BIIB) Valuation After New Breakthrough SMA Nod And Positive Lupus Phase 3 Data Simply Wall St.

  Biogen (BIIB) is back in focus after the FDA granted Breakthrough Therapy Designation to its spinal muscular atrophy candidate salanersen, while fresh Phase 3 lupus data with partner UCB highlighted d

• BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag Zacks

  Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.

• Repligen (RGEN) Down 3.2% Since Last Earnings Report: Can It Rebound? Zacks

  Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

• Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care Zacks

  OCGN is advancing gene-agnostic eye therapies across retinal diseases, with key trial data and regulatory milestones approaching in 2026 and 2027.